By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Growth in its Life Sciences and Diagnostics segment helped Danaher's second-quarter sales expand 15 percent year over year, the company reported today.

Overall, sales increased to $3.71 billion for the three months ended July 1, compared to $3.22 billion a year ago, helped along by a 31 percent increase in its Life Sciences and Diagnostics business, which spiked to $704.8 million from $540.1 million a year ago.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.